FLOWER MOUND, Texas, Aug. 12 AmericanHealthChoice, Inc. (Pink Sheets: AMHI), http://www.americanhealthchoice.com, amedical services company with medical clinics in Texas and Tennessee, ispleased to announce the launch of the U.S. FDA approved OmniBody Scan, aninfrared thermal imaging camera that will be able to detect patterns ofabnormality within the human body. In conjunction with existing technologies,the OmniBody Scan (http://www.omnibodyscan.com) will be able to identifyproblems early enough for prevention and treatment.
According to Pat McGlashan, President of RehabCo, a division of AMHI, "Ourinitial focus will be the worldwide problem of breast cancer. The dilemmathat all women have is that having X-rays to detect breast cancer may causebreast cancer. The OmniBody Scan is a non-invasive tool that will have noharmful side effects. The earlier that breast cancer is detected equates to amuch higher chance of survival, especially with Inflammatory Breast Cancer(IBC)."
The OmniBody Scan is manufactured specifically for American HealthChoiceby a respected infrared imaging manufacturer with years of successfulexperience in this field. Efforts have begun to solicit resellers topenetrate the U.S. market with both the OmniBody Scan and the Company'sadjunct support system of providing high quality "interpretations" of theinfrared images.
"We wish to express our sincere thanks to our investors and shareholdersfor their patience in allowing us to finally introduce the OmniBody Scan withthe proper FDA approvals and technology. This is the product that we wantedfrom the beginning. While it is manufactured by a different company than theoriginal version, it adheres to the highest standards of thermography. It iseasy to use and offers a very high grade of technology and quality. This is agreat market for American HealthChoice to enter and, while it took longer thananticipated, we have great expectations on the results both short and longterm," said Mr. McGlashan.
Five years ago, the U.S. Preventive Services Task Force, an independentpanel of experts in primary care and prevention, examined data from numerousclinical trials and estimated that screening mammography every one or twoyears in women in their 40s resulted in a 15 percent decrease in breast cancermortality after 14 years of follow-up. But, analyses also made note of thepotential harm of screening, including radiation exposure, procedure-associated pain, false-positive results, over-diagnosis and potentiallyunnecessary treatment.
"The Company continues it litigation against Texas Infrared, the originalmanufacturer, in the matter of the OmniBody Scan and we anticipate an outcomefavorable to American HealthChoice," said Dr. John W. Stucki, CEO.
The OmniBody Scan, a non-invasive technology with absolutely no harmfulside effects, is available today. For additional information or to become anauthorized reseller, please contact Pat McGlashan at 817-837-8000, ext. 222,or [email protected]
Safe Harbor Statement: The statements in this release that relate tofuture plans, expectations, events, performance, and the like are forward-looking statements within the meaning of the Private Securities LitigationReform Act of 1995 and the Securities Exchange Act of 1934. Actual results orevents could differ materially from those described in the forward-lookingstatements due to a variety of factors, including those set forth in theCompany's report on Form 10-KSB filed with the Securities and ExchangeCommission.CONTACT: Dr. J.W. Stucki, CEO American HealthChoice, Inc. 817/837-8000 Paul Knopick E & E Communications 949/707-5365 [email protected]
SOURCE American HealthChoice, Inc.